Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
98% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PGNX' s Cash to Debt Range Over the Past 10 Years
Min: 65  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.71
PGNX's Equity to Asset is ranked higher than
53% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PGNX: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
PGNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.89 Max: 0.98
Current: 0.71
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
98% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -1.17
M-Score: -8.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1493.42
PGNX's Operating margin (%) is ranked lower than
81% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. PGNX: -1493.42 )
Ranked among companies with meaningful Operating margin (%) only.
PGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 12.17
Current: -1493.42
-878.82
12.17
Net-margin (%) -1466.58
PGNX's Net-margin (%) is ranked lower than
81% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. PGNX: -1466.58 )
Ranked among companies with meaningful Net-margin (%) only.
PGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 12.24
Current: -1466.58
-876.82
12.24
ROE (%) -38.18
PGNX's ROE (%) is ranked lower than
56% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. PGNX: -38.18 )
Ranked among companies with meaningful ROE (%) only.
PGNX' s ROE (%) Range Over the Past 10 Years
Min: -96.05  Med: -33.65 Max: 16.86
Current: -38.18
-96.05
16.86
ROA (%) -28.92
PGNX's ROA (%) is ranked lower than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. PGNX: -28.92 )
Ranked among companies with meaningful ROA (%) only.
PGNX' s ROA (%) Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: -28.92
-79.08
14.53
ROC (Joel Greenblatt) (%) -451.28
PGNX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. PGNX: -451.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1616.79  Med: -413.77 Max: 208.07
Current: -451.28
-1616.79
208.07
Revenue Growth (3Y)(%) -36.40
PGNX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PGNX: -36.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.7  Med: -16.20 Max: 73.2
Current: -36.4
-55.7
73.2
EBITDA Growth (3Y)(%) -45.50
PGNX's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. PGNX: -45.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.5  Med: -7.00 Max: 51.4
Current: -45.5
-45.5
51.4
EPS Growth (3Y)(%) -40.60
PGNX's EPS Growth (3Y)(%) is ranked lower than
88% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PGNX: -40.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.5  Med: 1.30 Max: 221.1
Current: -40.6
-73.5
221.1
» PGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PGNX Guru Trades in Q1 2015

Chuck Royce 1,707,850 sh (+1.49%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson 1,288,454 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 2,342,388 sh (-1.19%)
» More
Q2 2015

PGNX Guru Trades in Q2 2015

Chuck Royce 3,221,850 sh (+88.65%)
Paul Tudor Jones 2,387,708 sh (+1.93%)
Murray Stahl 67,200 sh (unchged)
Julian Robertson Sold Out
» More
Q3 2015

PGNX Guru Trades in Q3 2015

Ken Fisher 83,250 sh (New)
Paul Tudor Jones 2,392,099 sh (+0.18%)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 2,978,950 sh (-7.54%)
» More
Q4 2015

PGNX Guru Trades in Q4 2015

Ken Fisher 140,191 sh (+68.40%)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 2,282,250 sh (-23.39%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 4.41
PGNX's Forward P/E is ranked higher than
90% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. PGNX: 4.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.91
PGNX's P/B is ranked lower than
59% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. PGNX: 2.91 )
Ranked among companies with meaningful P/B only.
PGNX' s P/B Range Over the Past 10 Years
Min: 1.08  Med: 3.55 Max: 16.48
Current: 2.91
1.08
16.48
P/S 100.25
PGNX's P/S is ranked lower than
94% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. PGNX: 100.25 )
Ranked among companies with meaningful P/S only.
PGNX' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 9.81 Max: 195
Current: 100.25
1.88
195
PFCF 133.67
PGNX's PFCF is ranked lower than
92% of the 269 Companies
in the Global Biotechnology industry.

( Industry Median: 27.55 vs. PGNX: 133.67 )
Ranked among companies with meaningful PFCF only.
PGNX' s PFCF Range Over the Past 10 Years
Min: 10.93  Med: 34.29 Max: 260
Current: 133.67
10.93
260
POCF 133.67
PGNX's POCF is ranked lower than
90% of the 395 Companies
in the Global Biotechnology industry.

( Industry Median: 27.92 vs. PGNX: 133.67 )
Ranked among companies with meaningful POCF only.
PGNX' s POCF Range Over the Past 10 Years
Min: 10.93  Med: 32.39 Max: 260
Current: 133.67
10.93
260
EV-to-EBIT -4.16
PGNX's EV-to-EBIT is ranked lower than
99.99% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. PGNX: -4.16 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.8  Med: -4.35 Max: 301.4
Current: -4.16
-50.8
301.4
EV-to-EBITDA -4.21
PGNX's EV-to-EBITDA is ranked lower than
99.99% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. PGNX: -4.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
PGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.8  Med: -4.50 Max: 233.2
Current: -4.21
-132.8
233.2
Current Ratio 9.85
PGNX's Current Ratio is ranked higher than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. PGNX: 9.85 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.84 Max: 32.92
Current: 9.85
2.67
32.92
Quick Ratio 9.85
PGNX's Quick Ratio is ranked higher than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PGNX: 9.85 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.84 Max: 32.92
Current: 9.85
2.67
32.92
Days Sales Outstanding 184.20
PGNX's Days Sales Outstanding is ranked lower than
89% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. PGNX: 184.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.9  Med: 32.86 Max: 180.24
Current: 184.2
0.9
180.24
Days Payable 2.00
PGNX's Days Payable is ranked lower than
93% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. PGNX: 2.00 )
Ranked among companies with meaningful Days Payable only.
PGNX' s Days Payable Range Over the Past 10 Years
Min: 167.51  Med: 917.89 Max: 21875.67
Current: 2
167.51
21875.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.57
PGNX's Price/Net Cash is ranked higher than
56% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: 5.54 vs. PGNX: 5.57 )
Ranked among companies with meaningful Price/Net Cash only.
PGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.18 Max: 22.41
Current: 5.57
1.59
22.41
Price/Net Current Asset Value 4.83
PGNX's Price/Net Current Asset Value is ranked higher than
56% of the 893 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PGNX: 4.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 5.69 Max: 18.68
Current: 4.83
1.48
18.68
Price/Tangible Book 4.66
PGNX's Price/Tangible Book is ranked lower than
52% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. PGNX: 4.66 )
Ranked among companies with meaningful Price/Tangible Book only.
PGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.22  Med: 4.83 Max: 13.45
Current: 4.66
1.22
13.45
Price/Median PS Value 10.28
PGNX's Price/Median PS Value is ranked higher than
62% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. PGNX: 10.28 )
Ranked among companies with meaningful Price/Median PS Value only.
PGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.28 Max: 14.67
Current: 10.28
0.23
14.67
Earnings Yield (Greenblatt) (%) -24.00
PGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. PGNX: -24.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 1.80 Max: 10.2
Current: -24
0.3
10.2

More Statistics

Revenue(Mil) $45
EPS $ -0.64
Beta3.48
Short Percentage of Float21.25%
52-Week Range $3.61 - 11.15
Shares Outstanding(Mil)69.81

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 6 103 177 254
EPS($) -0.60 0.47 0.91 1.68
EPS without NRI($) -0.60 0.47 0.91 1.68

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report Feb 09 2016
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Feb 01 2016
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Feb 01 2016
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and... Jan 12 2016
Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for... Jan 07 2016
Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for... Jan 07 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 05 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of... Dec 28 2015
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
Progenics Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 18 2015
Stock Updates on Biotechnology -- Xenoport, Progenics Pharma, Ocata Therapeutics, and Vanda Pharma Dec 17 2015
PROGENICS PHARMACEUTICALS INC Financials Dec 08 2015
Progenics (PGNX) Reaches Target Enrolment in Azedra Study Dec 04 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 04 2015
Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra™ Dec 03 2015
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : December 1, 2015 Dec 01 2015
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 1,... Dec 01 2015
Here is What Hedge Funds Think About Memorial Production Partners LP (MEMP) Nov 30 2015
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : November... Nov 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK